OXYTROL: HCP - OXYTROL Highlights

U.S. Prescribing Information >> | OXYTROL Highlights >> | OXYTROL Clinical Results >> | Reimbursement Information >>
Frequently Asked Questions >> | Instructions for Your Patients >>

OXYTROL Highlights
Provide them relief with convenience

An easy-to-wear patch for your patients

Consistent adhesion observed in more than 4700 evaluations [1*]
— System remained intact in 99.6% of evaluations
— Complete attachment was observed in 99.3% of evaluations
Bathing, swimming, or exercising should not affect adhesion [7†]
Patients simply apply OXYTROL to dry, intact skin on the abdomen, hip, or buttock—absorption is bioequivalent [1]
— Select a new site with each application
— Avoid reapplication to the same site within 7 days

The most common application-site adverse events were pruritus and erythema. [1]

Please see full prescribing information for OXYTROL

Oxytrol Highlight References:
* In 2 clinical studies, consistent adhesion was defined as 75% of the surface of the transdermal system being in contact with the patient's skin as evaluated during a clinic visit.
† Patients who participated in the studies were not bound by any restrictions in activity.


	[1] OXYTROL® Prescribing Information. February 2003. [2] Dmochowski RR, Davila GW, Zinner NR, et al, for the Transdermal Oxybutynin Study Group. Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. J Urol. 2002;168:580-586. [3] Data on file, Watson Pharma, Inc. [4] Dmochowski RR, Sand PK, Zinner NR, et al. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology. 2003;62:237-242. [5] Appel RA, Chancellor MB, Zobrist RH, Thomas H, Sanders SW. Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects. Mayo Clin Proc. 2003;78:696-702. [6] Zobrist RH, Schmid B, Feick A, Quan D, Sanders SW.Pharmacokinetics of the R- and S-enantiomers of oxybutynin and N-desethyloxybutynin following oral and transdermal administration of the racemate in healthy volunteers. Pharm Res. 2001;18:1029-1034. [7] OXYTROL® Patient Prescribing Information.